LDE Stock Chart & Stats
€5.50
-€0.85(-13.18%)
At close: 4:00 PM EST
€5.50
-€0.85(-13.18%)
Day’s Range― - ―
52-Week Range€3.12 - €7.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€142.77M
Enterprise Value€481.27
Total Cash (Recent Filing)€20.80M
Total Debt (Recent Filing)€150.14M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.68Price Target Upside3.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.92
Revenue Forecast (FY)€107.03M
Bulls Say, Bears Say
Bulls Say
Sustained Cash GenerationTTM operating cash flow of $17.4M and free cash flow of $10.5M demonstrate the company can internally fund operations. Durable cash generation provides flexibility to support working capital, selective capex, debt service and reinvestment while pursuing margin recovery and contract scale.
Stable Gross Margins And EBITDAA steady gross margin near 31% with EBITDA roughly breakeven indicates core unit economics in CDMO fill-finish work are intact. If utilization and contract mix improve, operating leverage can push the business toward sustained profitability without relying solely on pricing increases.
Governance And Retention ToolsApproval of the 2026 Stock Incentive Plan and re-election of directors supports management continuity and gives the company equity-based tools to retain technical and operational talent. This reduces execution risk for complex CDMO projects and aids long-term capacity and quality delivery.
Bears Say
Very High LeverageDebt-to-equity around 7.2x represents significant leverage that sharply reduces financial flexibility. Elevated leverage increases refinancing, covenant and interest-rate risks, forcing reliance on consistent cash flow and limiting room for strategic investments or opportunistic capacity expansion.
Ongoing Net Losses And Revenue DeclineA TTM revenue decline of -8.13% alongside a net margin near -25% indicates the company has not established durable profitability. Continued losses hinder reinvestment, weaken balance sheet resilience, and make long-term recovery contingent on sustained top-line stabilization or structural cost improvements.
Low Equity And Negative ROEPersistently low equity and negative returns on equity reflect cumulative losses and a thin capital cushion. This limits the company's ability to absorb shocks, increases the likelihood of dilutive financing if capital is needed, and elevates execution risk during any operational setback.
Lifecore Biomedical News
LDE FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was €3.12 and its highest was €7.30 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is €142.77M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 12 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Undervalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in DE:LDE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LDE Stock 12 Month Forecast
Average Price Target
€5.68
▲(3.30% Upside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―